Cargando…

Evaluation of Reinfection in COVID-19 Patients in the World: A Narrative Review

Background: The evaluation of reinfection and the genetic structure of all human and virus genomes could help to develop programs and protocols for providing services and ultimately to prevent the disease by producing more effective vaccines. Therefore, the aim of this study was to investigate the p...

Descripción completa

Detalles Bibliográficos
Autores principales: Eshrati, Babak, Baradaran, Hamid Reza, Moradi, Ghobad, Dehghanbanadaki, Hojat, Azh, Nima, Soheili, Marzieh, Moetamed Gorji, Nogol, Moradi, Yousef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Iran University of Medical Sciences 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8840848/
https://www.ncbi.nlm.nih.gov/pubmed/35321379
http://dx.doi.org/10.47176/mjiri.35.144
_version_ 1784650716111962112
author Eshrati, Babak
Baradaran, Hamid Reza
Moradi, Ghobad
Dehghanbanadaki, Hojat
Azh, Nima
Soheili, Marzieh
Moetamed Gorji, Nogol
Moradi, Yousef
author_facet Eshrati, Babak
Baradaran, Hamid Reza
Moradi, Ghobad
Dehghanbanadaki, Hojat
Azh, Nima
Soheili, Marzieh
Moetamed Gorji, Nogol
Moradi, Yousef
author_sort Eshrati, Babak
collection PubMed
description Background: The evaluation of reinfection and the genetic structure of all human and virus genomes could help to develop programs and protocols for providing services and ultimately to prevent the disease by producing more effective vaccines. Therefore, the aim of this study was to investigate the presence and occurrence of COVID-19 reinfection through a narrative review study. Methods: We searched the Medline (PubMed), Embase, Scopus, Web of Science, Cochrane library, Ovid, and CINHAL databases. Inclusion criteria included all studies whose main purpose was to provide information about the occurrence or presence of reinfection in patients with COVID-19. An independent samples t test was used to compare the continuous outcomes between the 2 groups. Results: The mean duration of the first episode in the group with mild or moderate COVID-19 was 24.42±1.67 days, and it was 21.80±3.79 days in the group with severe COVID-19. The mean duration of the second episode (reinfection) in patients with mild or moderate form was 15.38 ± 5.57 days, and it was 19.20±2.98 days in patients with severe form. In both episodes, the duration of the disease did not significantly differ between the 2 groups (p=0.484 in the first episode; p=0.675 in the second episode), but the interval to the occurrence of reinfection in patients with the mild or moderate form was significantly longer than those with the severe form (p<0.001). In this instance, the time interval in patients with the mild or moderate form was 36.63±5.71 days while in those with the severe form of the disease it was 29.70±5.65 days. Besides, the genomes of the viruses isolated from the first and second episode were different. Conclusion: According to the results, all patients should be very careful about the severity of the second episode because of the more need for medical interventions for saving the patients. The interval between the first end and the second episode as well as the duration of each episode is highly important for better management of the disease.
format Online
Article
Text
id pubmed-8840848
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Iran University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-88408482022-03-22 Evaluation of Reinfection in COVID-19 Patients in the World: A Narrative Review Eshrati, Babak Baradaran, Hamid Reza Moradi, Ghobad Dehghanbanadaki, Hojat Azh, Nima Soheili, Marzieh Moetamed Gorji, Nogol Moradi, Yousef Med J Islam Repub Iran Review Article Background: The evaluation of reinfection and the genetic structure of all human and virus genomes could help to develop programs and protocols for providing services and ultimately to prevent the disease by producing more effective vaccines. Therefore, the aim of this study was to investigate the presence and occurrence of COVID-19 reinfection through a narrative review study. Methods: We searched the Medline (PubMed), Embase, Scopus, Web of Science, Cochrane library, Ovid, and CINHAL databases. Inclusion criteria included all studies whose main purpose was to provide information about the occurrence or presence of reinfection in patients with COVID-19. An independent samples t test was used to compare the continuous outcomes between the 2 groups. Results: The mean duration of the first episode in the group with mild or moderate COVID-19 was 24.42±1.67 days, and it was 21.80±3.79 days in the group with severe COVID-19. The mean duration of the second episode (reinfection) in patients with mild or moderate form was 15.38 ± 5.57 days, and it was 19.20±2.98 days in patients with severe form. In both episodes, the duration of the disease did not significantly differ between the 2 groups (p=0.484 in the first episode; p=0.675 in the second episode), but the interval to the occurrence of reinfection in patients with the mild or moderate form was significantly longer than those with the severe form (p<0.001). In this instance, the time interval in patients with the mild or moderate form was 36.63±5.71 days while in those with the severe form of the disease it was 29.70±5.65 days. Besides, the genomes of the viruses isolated from the first and second episode were different. Conclusion: According to the results, all patients should be very careful about the severity of the second episode because of the more need for medical interventions for saving the patients. The interval between the first end and the second episode as well as the duration of each episode is highly important for better management of the disease. Iran University of Medical Sciences 2021-11-01 /pmc/articles/PMC8840848/ /pubmed/35321379 http://dx.doi.org/10.47176/mjiri.35.144 Text en © 2021 Iran University of Medical Sciences https://creativecommons.org/licenses/by-nc/3.0/This is an open-access article distributed under the terms of the Creative Commons Attribution NonCommercial-ShareAlike 1.0 License (CC BY-NC-SA 1.0), which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
spellingShingle Review Article
Eshrati, Babak
Baradaran, Hamid Reza
Moradi, Ghobad
Dehghanbanadaki, Hojat
Azh, Nima
Soheili, Marzieh
Moetamed Gorji, Nogol
Moradi, Yousef
Evaluation of Reinfection in COVID-19 Patients in the World: A Narrative Review
title Evaluation of Reinfection in COVID-19 Patients in the World: A Narrative Review
title_full Evaluation of Reinfection in COVID-19 Patients in the World: A Narrative Review
title_fullStr Evaluation of Reinfection in COVID-19 Patients in the World: A Narrative Review
title_full_unstemmed Evaluation of Reinfection in COVID-19 Patients in the World: A Narrative Review
title_short Evaluation of Reinfection in COVID-19 Patients in the World: A Narrative Review
title_sort evaluation of reinfection in covid-19 patients in the world: a narrative review
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8840848/
https://www.ncbi.nlm.nih.gov/pubmed/35321379
http://dx.doi.org/10.47176/mjiri.35.144
work_keys_str_mv AT eshratibabak evaluationofreinfectionincovid19patientsintheworldanarrativereview
AT baradaranhamidreza evaluationofreinfectionincovid19patientsintheworldanarrativereview
AT moradighobad evaluationofreinfectionincovid19patientsintheworldanarrativereview
AT dehghanbanadakihojat evaluationofreinfectionincovid19patientsintheworldanarrativereview
AT azhnima evaluationofreinfectionincovid19patientsintheworldanarrativereview
AT soheilimarzieh evaluationofreinfectionincovid19patientsintheworldanarrativereview
AT moetamedgorjinogol evaluationofreinfectionincovid19patientsintheworldanarrativereview
AT moradiyousef evaluationofreinfectionincovid19patientsintheworldanarrativereview